Nassif David W. sold $219K of PHVS

Nassif David W. (CFO / CLO) sold 6,000 shares of Pharvaris N.V. (PHVS) at $36.47 ($0.22M total) on 2026-09-21.

Original reporting
SEC EDGAR · Nassif David W.
Published Sep 23, 2026, 2:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 2:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
low confidence
Mentioned
$PHVS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The CFO's sale modestly reduces his ownership, unlikely to move the stock significantly.

02

Market read

Insider sale is a routine disclosure with limited trading relevance.

03

What to watch

Potential upcoming corporate actions not disclosed; monitor future filings.

Relevance 4/10Novelty 4/10Timing: filed today

Background

Form 4 filing reports insider transactions required by SEC; provides transparency on officer holdings.

Company-level read

Ticker impact

$PHVSNeutralLow confidence
Context

CFO Nassif David W. sold 6,000 shares for $218,800, reducing his stake to 114,300 shares.

Expected impact

Potential slight downward pressure, but likely negligible.

Evidence & confidence

Sale size is modest relative to market cap and insider holdings; no 10b5-1 plan.

Market effects

No immediate sector impact; biotech sector unchanged.

US market only; no regional effect.

Low global relevance.

Counterpoint

Insider sale could signal concerns, but size is too small to infer material risk.

Key entities

  • Pharvaris N.V.

    Biotech firm listed on Nasdaq under ticker PHVS.

  • Nassif David W.

    Chief Financial Officer and Chief Legal Officer of Pharvaris.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.